MitoRx Therapeutics Announces Scientific Advisory Board, Chief Development Officer and Finance Director.

OXFORD ENGLAND, 7 MARCH 2023. MitoRx Therapeutics (MitoRx), a biotechnology company developing revolutionary therapeutics that reverse mitochondrial dysfunction to arrest the progression of degenerative diseases, announces Christine Charman as Chief Development Officer, David Richardson as Finance Director, and four appointments to its Scientific Advisory Board (SAB): Prof Chas Bountra, Prof Dame Kay Davies, Prof Laurent Servais, and Dr Bernd C Schwahn.

Read full release.